Trial Profile
Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on acute events in patients with acute myocardial infarction: multicenter randomized controlled trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2020
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; Pitavastatin
- Indications Myocardial infarction
- Focus Pharmacodynamics
- 20 Feb 2020 Status changed to active, no longer recruiting.
- 05 Sep 2017 New trial record